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Abstract
Purpose Proliferative vitreoretinopathy
(PVR) is the leading cause of failure of surgery
for rhegmatogenous retinal detachment.
Although indirect evidence suggests that this
disease might be autoimmune in nature,
direct proof for this hypothesis is lacking.
The purpose of this study was to determine in
a murine model whether PVR can develop
in the absence of T- or B-cell immunity.
Methods Four- to six-week-old Rag-1 gene
knockout (KO) and congenic wild-type mice
(WT) on the C57.Bl/6 background were
studied. PVR was induced by intravitreal
injection of 3ll dispase at the concentration of
0.2 U/ll. PVR development was monitored by
electroretinograms, the macroscopic observation
of hemorrhage, cataract, retinal folds, and of an
uneven iris, as well as the histological detection
of epiretinal membranes on haematoxylin–eosin
stained tissue. Additionally, immunoﬂuorescence
analysis was performed. These manifestations
of PVR were assessed 1, 2, 4, 6, and 8 weeks
after the intravitreal injection.
Results The data showed that the immune-
deﬁcient Rag-1 KO mice developed PVR with
similar kinetics and severity as did the
fully immune competent congenic WT mice.
Carboxyﬂuorescein diacetate succinimidyl
ester-labeled T cells that are speciﬁc for
ovalbumin were detected in the inﬂamed
vitreous and retina showing that T cells that
are not speciﬁc for autoantigens present in the
eye can migrate to PVR lesions. Therefore, the
mere presence of T cells in PVR lesions does
not imply an autoimmune pathogenesis.
Conclusion This study suggests that T- and
B-cell immunity is not essential for the
induction of PVR.
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Introduction
Proliferative vitreoretinopathy (PVR) can occur
as a severe complication after surgery for
rhegmatogenous retinal detachment.
1 It is
characterized by the formation of a scar-like
ﬁbrous tissue in the vitreous that contains
myoﬁbroblasts derived form transdifferentiated
retinal pigment epithelial cells or glial cells.
2,3
The pathogenesis of PVR is still not completely
understood. Indirect evidenceFbut no
proofFhas been provided in favor of an
autoimmune hypothesis as the consequence of
which PVR frequently has been referred to as
autoimmune complication of eye surgery. The
autoimmune hypothesis has been apparently
supported by the observation that a PVR-like
disease can be induced in rabbits by
immunization with the retinal autoantigens
opsin, S antigen (S-Ag), and interphotoreceptor
retinoid-binding protein.
4 In addition,
apparently arguing for the autoimmune
hypothesis, PVR patients display signs of active
immune processes in their epiretinal or
subretinal membranes, vitreous cavity,
subretinal ﬂuid, and serum samples.
5–11 Thus,
deposits of IgG, IgA, and IgE antibodies and
complement fragments C1q, C3c, and C3d can
be detected in the epiretinal or subretinal
membranes of PVR lesions, along with
inﬁltrating CD4 and CD8 T cells, B cells, and
macrophages. Moreover, increased expression
of CD95-ligand and/or HLA-DR molecules on
these immune cells suggests that they are in an
activated state. Similar signs of immune activity
have been reported for the cells present in the
vitreous cavity or subretinal ﬂuid of PVR
patients.
8,12–15 Sera of PVR patients contain
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16 and S-Ag-speciﬁc
autoantibodies.
17 The presence of these autoantibodies in
particular has been thought to support the autoimmune
hypothesis because the involvement of antigen-speciﬁc
CD4 cells, so called T-cell help, is a prerequisite for B-cell
responses to mammalian protein antigens in general, and
to protein antigens of the eye in particular. Therefore, the
presence of autoantibodies directed against protein
antigens of the eye implies that auto reactive CD4 cells
with the same protein antigen speciﬁcity have engaged in
an autoimmune response.
18 Although all the above
ﬁndings are consistent with an autoimmune hypothesis
for PVR, they do not prove it, and it has been difﬁcult to
establish whether the immune reactions seen represent
the cause of the disease, or merely accompany it.
1
Unambiguous proof for or against the autoimmune
hypothesis of PVR requires a model in which the
inﬂammatory sequelae after ocular injury can be studied in
the presence or absence of a functional immune system.
The classic PVR model does not readily lend itself to such a
study because there are no congenic immunodeﬁcient/
immunesufﬁcient rabbit strains. We therefore established
and studied a murine PVR model that involved C57.Bl/6
wild-type (WT) mice (that have a fully functional immune
system) and congenic Rag-1 gene knockout (KO) mice
(that are profoundly immunodeﬁcient as they lack the
gene that is required to generate antigen receptors for
T and B lymphocytes). The purpose of this study was to
determine whether T and B cells capable of mounting
an autoimmune response are required for the development
of PVR.
Materials and methods
Mice
B6. 129S7-Rag1
tmiMom/J mice,
19 4–6 week old, on a
C57.Bl/6 background, were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA) and used to set up a
breeding colony. Homozygous C57.Bl/6-Tg (OT-II.2a)-
Rag1
tm1Mom mice,
20 bearing transgenes for the expression
of an ovalbumin (OVA) -speciﬁc T-cell receptor (TCR),
were purchased form Taconic Farms, Inc. (Germantown,
NY, USA). These mice were bred at our facility to the
Rag
–/– background to assure exclusive T-cell expression
of the TCR transgenes. Animal husbandry and
experimental procedures were approved by the Animal
Research Committee of Zhongshan Ophthalmic Center,
Sun Yat-sen University. All animals were housed in a
speciﬁc pathogen-free biohazard level-2 facility main-
tained by the Zhongshan Ophthalmic Center, Sun Yat-sen
University (Guangzhou, China) in accordance with the
‘Association of Assessment and Accreditation of
Laboratory Animal Care’ (AAALAC) guidelines.
Murine PVR model induced by intravitreal dispase
injection
Murine PVR was induced by dispase (GIBCO, Tokyo,
Japan) as previously described.
21 Four to six weeks
old female mice were anesthetized with 4.3% chloral
hydrate (0.01ml/g, from Zhongshan Ophthalmic Center,
Sun Yat-sen University). Pupils were dilated with
0.5% tropicamide (from Shenyang SinQi Pharmaceutical
Co., Ltd, Shenyang, China). Intravitreal injections were
made in the dorsonasal quadrant of the right eye. Three
ml dispase at the concentration of 0.2U/ml was injected
into the vitreous cavity with a Hamilton syringe ﬁtted
with a 30-G needle. Control animals were injected
with 3ml of sterile saline. All experimental procedures
adhered to guidelines of the ‘Association for Research
in Vision and Ophthalmology Resolution on the Use
of Animals in Ophthalmic and Vision Research’.
Follow-up examinations, PVR assessment
After intravitreal injection, at the time points speciﬁed,
the eyes were examined with a surgical microscope.
Corneal- and lens opacities, intravitreal hemorrhage, and
the fundus were assessed at each time point. Intravitreal
hemorrhage and cataract development are the hallmarks
of PVR, but might not be stringent enough criteria for its
unambiguous diagnosis in particular after mechanical
injury of the eye.
22 Therefore, for this study, we adopted
an evaluation system introduced by Canto ´ Soler et al
21
that in addition to (a) hemorrhage and (b) cataract
requires the development of (c) retinal folds, of (d)
epiretinal membranes (EM), and (e) of an uneven iris (the
latter indicating retinal traction detachment). Moreover,
all these hallmarks of the disease were recorded at 1, 2, 4,
6, and 8 weeks after the injection of the eye. To quantify
the severity of the ocular lesions, the cumulative score for
the PVR symptoms a–e was established over the entire
observation period.
Electroretinography (ERG)
Electroretinograms were obtained from mice at 1, 2, 4, 6,
and 8 weeks after intravitreal injection in a full-ﬁeld
dome using methods that are analogs to those commonly
used for humans in ophthalmology. The stimuli used
were according to the speciﬁcations by the ‘International
Society for Clinical Electrophysiology of Vision’
standard.
23 The eyes were dilated with 0.5% tropicamide
and dark-adapted for at least 30min. Mice were
anesthetized with a saline solution containing ketamine
hydrochloride (30mg/kg) and chlorpromazine
hydrochloride (15mg/kg). A gold-wire coil placed on
one cornea was referenced to a needle electrode in the
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Eyescalp. A needle electrode in the tail served as ground.
The recordings were made using the Roland Ganzfeld
system and PC-based signal acquisition and analysis
software (Fa. Roland Consult, Brandenburg, Germany).
The contralateral untreated eyes were used as controls.
Tissue preparation, histological, and
immunoﬂuorescence analysis
For histochemical studies, mice were killed at the
post-injection time points speciﬁed, eyes dissected,
and cryopreserved using OCT (Optimal Cutting
Temperature, Sakura Finetek USA, Inc., Torrance, CA,
USA). For immunoﬂuorescence analysis and
haematoxylin–eosin (H&E) staining, consecutive 6mm
thick sections of each sample were cut and thaw-
mounted onto poly-L-lysine-coated glass slides. For
confocal microscopy, double immunostaining was done
using two primary antibodies (incubating for 20h at
room temperature with both, simultaneously) and then
incubating with the secondary antibodies for 1h in the
dark. The following marker-speciﬁc antibodies were
used to detect cell types: astroglial cells (glial acidic
ﬁbrillary protein, GFAP, mouse monoclonal speciﬁc
for mouse GFAP, used at 1:500, from CHEMICON
International, Inc., Temecula, CA, USA), Mu ¨ller cells
(glutamine synthase (GS), rabbit polyclonal speciﬁc for
mouse GS, 1:50, from Abcam, Cambridge, UK), RPE
cells (RPE65, mouse monoclonal speciﬁc for mouse RPE,
1:100, from Abcam), ﬁbroblasts (alpha smooth muscle
actin, a-SMA, rabbit polyclonal speciﬁc for mouse a-
SMA, 1:100, from Abcam), macrophages (F4/80, rat
monoclonal speciﬁc for mouse F4/80, 1:10, from
Abcam), T lymphocytes (anti-CD3, rat monoclonal
speciﬁc for mouse CD3, 1:50, from R&D Systems, Inc.,
Minneapolis, MN, USA), and NK cells (anti-CD56, rabbit
polyclonal antibody speciﬁc for mouse CD56, 1:100 from
Boster Biological Technology, WuHan, China). Three
secondary antibodies were used in this study: R-
phycoerythrin-conjugated goat anti-rat IgG (1:10, from
Southern Biotechnology Associates, Inc., Birmingham,
AL, USA), R-phycoerythrin-conjugated goat anti-mouse
IgG (1:10, from Southern Biotechnology Associates, Inc.)
and ﬂuorescein isothiocyanate-labeled goat anti-rabbit
IgG (1:10, from KPL, Gaithesburg, MD, USA). Sections
were washed four times with PBS (5min each time) and
mounted on coverslips in Antifade Solution (Applygen
Technologies Inc., Beijing, China) for observation with a
ﬂuorescence microscope.
Tracking adoptively transferred OT-II cells in mice
OT-II mice are transgenic for a pair of TCR chains that
encode a TCR speciﬁc for OVA peptide 323–339 when
presented on the MHC class II molecule, I-A
b. Therefore,
all CD4 cells are OVA 323–339-speciﬁc in OT-II mice
that are bred with Rag KO mice to avoid the
rearrangement of endogenous TCR genes. Such OVA
323–339 peptide-speciﬁc TCR transgenic CD4þ T cells
were isolated from spleens and lymph nodes of OT-II
Rag KO mice. CD4þ Tcells, adjusted to 4 10
6 cells/ml,
and were activated by culturing with the OVA 323–339
peptide (1mg/ml, from Anaspec, Inc., San Jose, CA, USA)
for 5 days in a humidiﬁed incubator at 371C, 9% CO2.
Then the OVA-speciﬁc CD4
þ T cells were washed and
incubated with Carboxyﬂuorescein diacetate succini-
midyl ester (CFSE; Molecular Probes, Inc., Grand Island,
NY, USA) at a ﬁnal concentration of 4mg/ml at 371C for
10min. Then the cells were washed, adjusted to 4 10
6
cells/ml, and one million cells (in 0.25ml) were injected
into the mice via their lateral tail vein. The recipient Rag
KO mice were at the same time treated with intravitreal
dispase injection and were killed at ﬁve time points (after
12, 24, 48, 72, and 96h). Eyes and spleens were processed
for OCT. Frozen sections were stained with anti-CD3
antibody (the second antibody was R-phycoerythrin-
conjugated goat anti-rat IgG) and the number of CFSE,
CD3 double positive cells was established. Three mice
per time point were studied, and experiments for each
condition were reproduced at least twice.
Statistical analysis
PVR incidences were compared among the time points
using w
2 test. Data of Skot ERG were compared by
Student’s t-test. A value of Po0.05 was considered
signiﬁcant.
Results
Rag-1 KO mice develop PVR
Figure 1 shows that immune-deﬁcient Rag-1 KO mice
develop all cardinal features of PVR after intravitreal
injection of dispase (Figure 1a). Formation of marked
EMs and tractional retinal detachment was seen in the
vitreous cavity (Figure 1b). In the EM cells, characteristic
of PVR were detected, namely glial cells, ﬁbroblasts,
RPE-, and Mu ˆller cells staining for GFAP, a-SMA, RPE65,
and GS, respectively (Figure 1c).
Rag-1 KO and WT mice show similar kinetics and
severity of PVR disease
The rate at which PVR developed after dispase injection
was monitored in Rag-1 KO and WT mouse strains to
assess the severity and kinetics of PVR development in
the absence or presence of a functional adaptive immune
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Eyesystem. In both type of mice, the macroscopic signs of the
disease developed in parallel. In both the groups, the ﬁrst
signs of PVR appeared 2 weeks after dispase injection,
affecting about 25% of the mice (Figure 2a). The
percentages of PVR-positive mice gradually increased in
the subsequent weeks reaching about 70% for both the
groups by 8th week. Statistical analysis showed no
signiﬁcant difference between the Rag KO and the
WT group at weeks 2, 4, 6, and 8 with P-values of
0.2163, 0.2503, 0.2176, and 0.2642, respectively.
Histological studies were performed to compare the
kinetics and severity of the dispase-induced disease in
KO and WT mice (Figure 2b). Mice of both groups were
killed at 1, 2, 4, 6, and 8 weeks and HE-stained frozen
sections of their eyes were studied. PVR kinetics and
severity did not markedly differ between the Rag KO
and the WT mice at weeks 2, 4, 6, and 8.
The severity of PVR was also compared in the two
groups of mice by Skot ERG (Figure 2). For dispase-
injected eyes there was no statistically signiﬁcant difference
in a-wave (P¼0.3454) and b-wave amplitudes (P¼0.5374)
of the WT and KO group. The contralateral untreated eyes
were used as controls. The untreated eyes of dispase-
injected mice also showed no signiﬁcant difference in
a-wave (P¼0.4053) or b-wave amplitudes (P¼0.5039).
In WT and Rag-1 KO mice neutrophilic inﬁltration
dominates the initial inﬂammatory reaction, occurring
with similar kinetics
We harvested eyes from KO and WT mice that were
untreated, or 4, 8, 12, 24, and 48h and 5 days after
injection of 3ml of dispase. The eyes of control mice were
injected with 3ml saline, and studied at these time points.
HE staining showed that polymorphonuclear neutrophils
were the main inﬁltrating cell type in the eyes of
dispase-injected KO and WT mice. In both strains, the
neutrophils started to appear 8h post injection, peaked at
24–48h, and decreased by day 5 (Figure 3). In contrast,
eyes of the saline-injected KO or WT mice did not show
an inﬁltrate at any of these time points.
Bystander T cells are recruited into the PVR inﬁltrate
We detected T cells in PVR lesions of WT mice at the
chronic stage of the inﬂammatory process. Our
observation, however, that PVR develops at a similar rate
and severity in Rag-1 KO and WT mice suggests that
these Tcells in PVR regions might be bystander cells, that
is, T cells with speciﬁcity for irrelevant antigens that are
non-speciﬁcally recruited to the site of inﬂammation.
To test this possibility, we studied whether Tcells speciﬁc
for OVA (an irrelevant antigen in the context of PVR)
would migrate into PVR lesions. OVA-speciﬁc TCR
transgenic T cells (that in addition were Rag-1
 /  to
assure that they express no additional endogenous TCR
chains, and thus are speciﬁc for OVA only) were used to test
this hypothesis. Such T cells were labeled with CFSE and
injected into dispase-treated mice. CFSE-labeled cells were
detected in the inﬂamed vitreous and retina at 48 and 72h
time point (Figure 4) showing that bystander T cells can
migrate to PVR lesions. Thus, the presence of T cells in the
EM 
EM 
EM
ab
c-1 c-3
c-2 c-4
c-5 c-7
EM 
c-6 c-8
Figure 1 Rag-1 KO mice develop all cardinal features of PVR.
Representative PVR manifestations are shown for a total of
45 Rag-1 KO mice studied 2–8 weeks after injection of dispase.
(a) Traction membrane in dispase-injected eye as indicated by
arrow. (b) Proliferative membrane in vitreal cavity and retinal
detachment as indicated by arrow. (c) Immunoﬂuorescence
staining for a-SMA (c-1), GFAP (c-2), GS (c-5), and RPE-65 (c-6)
in the epiretinal membrane (EM), and Hoechst 33342 staining to
mark cell nuclei with the EM (c-3 and c-7). c-4 is the merged
picture of c-1–c-3, and c-8 is the merged picture of c-5–c-7
(triple staining).
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EyePVR inﬁltrate does not imply that those T cells are speciﬁc
for autoantigens expressed in the eye; their presence does
not imply an autoimmune pathogenesis.
Discussion
The data presented here establish that autoimmunity is
not required for the development of dispase-induced
PVR in C57.Bl/6 mice as T- and B-cell-deﬁcient Rag-1 KO
animals develop PVR with similar kinetics and severity
than WT mice. We further show that the presence of
T cells in PVR lesions does not provide evidence for an
autoimmune etiology, as Tcells with irrelevant speciﬁcity
for autoantigens present in the eye (that is, Tcells speciﬁc
for OVA) are readily recruited to PVR lesions. To our
knowledge this is the ﬁrst report that clearly establishes
that autoimmune reactions are not required for the
pathogenesis of PVR. As detailed in the Introduction, the
autoimmune hypothesis has relied on indirect evidence,
such as the presence of T cells, which, however, can also
be interpreted within the framework of non-speciﬁc
inﬂammatory reactions mediated by the cells of innate
immunity. Data that were interpreted to argue against the
autoimmune hypothesis are also rather indirect. Thus,
Bali et al
24 showed that interleukin-10 had no effect on the
clinical progression of PVR. Although IL-10 can inhibit
T cells, it promotes B-cell responses
25 and as such may
have little net impact on an autoimmune disease.
In contrast to the ﬁndings of this study it has been
reported that S-Ag-speciﬁc autoantibodies can be
detected in PVR.
16 The presence of such antibodies
implies that S-Ag-speciﬁc autoreactive B cells have
engaged in an autoimmune response in PVR, and as
the production of such antibodies is dependent on
antigen-speciﬁc help by CD4 cells, by interference, that
is, an autoimmune T-cell response has been engaged.
Autoimmune reactions, however, can accompany tissue
injury without causing immune pathology.
26 The
S-Ag-speciﬁc autoantibodies that accompany PVR
might be indicative of such non-pathogenic, secondary,
b
c
PVR percentages
0
10
20
30
40
50
60
70
80
12468
Weeks after dispase injection
%
KO
WT
a
C-1
C-2
Skot ERG
KO Control WT Control 
Skot ERG
KO PVR  WT PVR 
C-3
a-wave
0
10
20
30
40
50
60
70
WT KO
u
V
Control
PVR
b-wave
0
20
40
60
80
100
120
140
160
180
WT KO
u
V
Control
PVR
Figure 2 Development of clinical PVR in Rag-1 KO and WT mice after dispase injection. A total of 10 mice in each group were
injected intraocularly with 0.2U/ml dispase. At the time points speciﬁed, the eyes were examined for: (a) macroscopic presentation of
PVR symptoms; and (b) histological evidence for PVR as established on H&E-stained sections. (c) Skot ERGs recording a- and b-wave
amplitudes. The contralateral untreated eyes were used as controls. The data in both panels represent the cumulative results obtained
on 25 Rag-1 KO mice after dispase injection.
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EyeDispase-injected
48 h
Dispase-injected
48 h KO WT
KO WT Dispase-injected
48 h
Dispase-injected
48 h
KO 48 hr
KO 48 hr
WT WT
a
b
c
Figure 3 Early inﬂammatory inﬁltration occurred at the same speed in WTand KO mice. (a) H&E staining of the retina after dispase
or saline injection. (b) H&E staining of the aqueous angle. Arrows indicate neutrophils. (c) Immunoﬂuorescence analysis showing the
absence of T cells (CD3
þ), macrophages (F4/80
þ), and NK cells (CD56
þ) 48h after dispase injection.
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Eyeautoimmune reactions. What then makes the difference
between pathogenic and non-pathogenic autoimmunity?
In the case of S-Ag, the answer seems to be that it is the
engagement of T cells, rather than of B cells and
antibodies. Active immunizations with S-Ag can cause
an autoimmune disease, experimental allergic uveitis
that entails PVR-like manifestations. While S-Ag-speciﬁc
antibodies are non-pathogenic, CD4 cells of certain
effector class(es) can mediate the autoimmune pathology.
The in vivo differentiation of such CD4 cells requires the
48 hr
72 hr
Figure 4 Detection of OVA-speciﬁc T cells in PVR lesions at 48 and 72h time point. OVA-speciﬁc, OT II TCR-transgenic T cells
were labeled with CFSE and injected i.v. into congenic Rag-1 KO mice that received a simultaneous intraocular dispase injection.
The mice were killed 12, 24, 48, 72, and 96h later and cryosections of their eyes were studied for the presence of green-ﬂuorescent
(CFSE positive) cells. Hoechst 33342 dye was used to stain nuclei of the tissue blue. Anti-CD3 staining is show in red.
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Eyeinjection of S-Ag with complete Freund’s adjuvant
(CFA).
27 For a related autoimmune model, experimental
allergic encephalomyelitis (that is, mediated by CD4 cells
after immunization with an autoantigen of the brain), we
recently reported that CFAFunlike other adjuvants
such as CpGFcauses the differentiation of autoantigen-
speciﬁc Th17 cells, and that this IL-17 is required for the
development of the autoimmune disease.
28 Thus, the
CD4 cells that provide autoantigen-speciﬁc help towards
the production of eye-antigen-speciﬁc autoantibodies
might not cause autoimmune pathology unless they are
of the Th17 lineage.
Our data show that dispase is a most potent activator
of the innate immune system. In Rag 1 KO mice, in
the absence of ampliﬁcation by T- and B-cell immunity,
dispase triggers an inﬂammatory reaction strong enough
to result in full-blown PVR. This severe non-speciﬁc
inﬂammation mediated by cells of innate immunity
seems to sufﬁce to bring about the changes that had been
interpreted as evidence for the autoimmune hypothesis:
deposits of antibodies and of complement, and the
presence of CD4 and CD8 T cells in the eye. Along these
lines, it should be noted that the fact that these T cells
display an activated phenotype in PVR lesions does not
imply that they actively recognize antigen at the site.
While resting T cells home to lymph nodes, activated
T cells preferentially migrate to sites of inﬂammation.
Tissue injury leads to non-speciﬁc inﬂammation. As an
intrinsic part the non-speciﬁc inﬂammatory reaction,
white blood cells of all lineages are recruited to the
injured site. Neutrophils dominate the inﬁltrate being the
prevalent cell type in blood, but T cells are also
recruited.
29 In brief, tissue injury triggers the local release
of prostaglandins and vasoactive amines that cause local
vasodilatation. As the capillary bed widens, blood ﬂow
slows down, and cells in the blood stream get to contact
the endothelial cells. Under the inﬂuence of IL-1 and
TNFa produced by macrophages in the inﬂamed tissue,
the endothelial cells in the local post capillary venules
start to express cell adhesion molecules, including
selectins. Expressing ligands for selectins, leukocytes
attach to these endothelia, and under the guidance of
PECAM proteins, the leukocytes migrate through the
vessel wall. Once in the interstitial space, the leukocytes
follow the chemotactic gradient to continue their
migration to the actual site of the injury. As neutrophils
prevail in the blood stream, in the ﬁrst 12h of
inﬂammation polymorphonuclear cells dominate the
inﬁltrate. These cells are short lived, however, and
during sustained non-speciﬁc inﬂammation long-lived
leukocytes such as macrophages and lymphocytes can
become dominant. The OVA-reactive T cells fall in this
latter category being recruited to the site of inﬂammation
irrespective of their antigen speciﬁcity.
Our data do not disprove the autoimmune hypothesis
for humans, or that in murine models secondary
autoimmune reactions could emerge possibly further
aggravating PVR. It, however, shows that the full clinical
and histological presentation of PVR can occur in the
complete absence of speciﬁc T- or B-cell immunity.
Moreover, our data show that already the initial non-
speciﬁc inﬂammatory reactions mediated by the innate
immune system sufﬁce to trigger these clinical
manifestations before the ampliﬁcation by adaptive
immune responses emerge.
PVR models have also been generated in the monkey
30
and rabbit,
31 and those models have been preferably
studied because the larger eyes of those animals facilitate
the clinical follow up. The murine model, however, is
unique in as much that inbred strains are available for
avoidance of genetic variability within the model.
Moreover, our data show that the initial non-speciﬁc
inﬂammatory reactions mediated by the innate immune
system is already sufﬁcient to trigger these manifestations.
We believe that of the PVR models available for different
species, dispase-induced PVR in C57.Bl/6 mice will gain
prevalence because the abundance of knockout/knock
in mice available facilitates mechanism-oriented
PVR research. Our use of the Rag-1 KO mice for PVR
research is the ﬁrst step in that direction.
A better understanding of the pathogenic mechanisms
that underlie PVR will help improve the therapeutic
approach to the disease. While it is unclear how well
murine dispase-induced PVR models the human disease,
our data clearly show that the innate immune system
alone can have a major role in inﬂammatory eye
pathology. In spite of the prevalence of the autoimmune
hypothesis, in the absence of an alternative that would
permit to selectively inactivate autoreactive T cells, the
present treatment of human PVR in the clinic targets the
innate immune system. Triamcinolone acetonide is being
used as an anti-inﬂammatory drug for the early stage
treatment and anti-proliferation treatment for the
advanced stage. If dispase-induced murine PVR indeed
models the human disease then future efforts to reﬁne an
anti-inﬂammatory approach that targets innate immunity
is likely to improve the present therapeutic success while
approaches that inhibit T cells might not be successful.
Summary
What was known before
K Although a great deal of information supports the role of
the immune system in the development of PVR, the role of
the immune system in the pathogenesis of PVR is still
unclear.
What this study adds
K This study suggests that T- and B-cell immunity is not
essential for the induction of PVR.
Assessment of the innate and adaptive immune system in PVR
W Zhang et al
879
EyeConﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This study was supported by the Natural National
Science Foundation of China (30973258) and the Science
and Technology Foundation of Guang Dong Province of
China (2010A090200074).
References
1 Pastor JC. Proliferative vitreoretinopathy: an overview.
Surv Ophthalmol 1998; 43: 3–18.
2 Pastor JC, de la Rua ER, Martin F. Proliferative
vitreoretinopathy: risk factors and pathobiology.
Prog Retin Eye Res 2002; 21: 127–144.
3 Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR.
In vivo models of proliferative vitreoretinopathy.
Nat Protoc 2007; 2: 67–77.
4 Broekhuyse RM, Rademakes AJ, Van Vugt AH, Winkens HJ.
Autoimmune responsiveness to retinal IRBP, S-antigen and
opsin in proliferative vitreoretinopathy. Exp Eye Res 1990;
50: 197–202.
5 Baudouin C, Fredj-Reygrobellet D, Gordon WC,
Baudouin F, Peyman G, Lapalus P et al. Immunohistologic
study of epiretinal membranes in proliferative
vitreoretinopathy. Am J Ophthalmol 1990; 110: 593–598.
6 Charteris DG, Hiscott P, Grierson I, Lightman SL.
Proliferative vitreoretinopathy. Lymphocytes in epiretinal
membranes. Ophthalmology 1992; 99: 1364–1367.
7 Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL,
Grierson I. Inﬂammatory cells in proliferative
vitreoretinopathy subretinal membranes. Ophthalmology
1993; 100: 43–46.
8 Tang S, Scheiffarth OF, Wildner G, Thurau SR, ELund O.
Lymphocytes, macrophages and HLA-DR expression in
vitreal and epiretinal membranes of proliferative
vitreoretinopathy. An immunohistochemical study.
Ger J Ophthalmol 1992; 1(3-4): 176–179.
9 Liversidge J, Sewell HF, Forrester JV. Interactions between
lymphocytes and cells of the blood-retina barrier:
mechanisms of T lymphocyte adhesion to human retinal
capillary endothelial cells and retinal pigment epithelial
cells in vitro. Immunology 1990; 71: 390–396.
10 Proenca R, Carvalho M, Proenca D, Verissimo J, Regadas I,
Travassos A. HLA antigens and lymphocytes in
proliferative vitreoretinopathy. Graefes Arch Clin Exp
Ophthalmol 1994; 232(1): 25–32.
11 Weller M, Heimann K, Bartz-Schmidt KU, Fontana A,
Esser P. CD 95 expression in traumatic proliferative
vitreoretinopathy: a target for the induction of apoptosis.
Ger J Ophthalmol 1995; 5: 332–337.
12 Baudouin C, Brignole F, Bayle J, Fredj-Reygrobellet D,
Lapalus P, Gastaudet P. Class II histocompatibility antigen
expression by cellular components of vitreous and
subretinal ﬂuid in proliferative vitreoretinopathy. Invest
Ophthalmol Vis Sci 1991; 32: 2065–2072.
13 El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ.
Intravitreal invading cells contribute to vitreal cytokine
milieu in proliferative vitreoretinopathy. Br J Ophthalmol
2001; 85: 461–470.
14 Martin F, Pastor JC, De La Rua ER, Mayo-Iscar A,
Garcı ´a-Arumı ´ J, Martı ´nez V et al. Proliferative
vitreoretinopathy: cytologic ﬁndings in vitreous samples.
Ophthalmic Res 2003; 35: 232–238.
15 Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran
F, Varinli S. Interleukin (IL)-6, interleukin (IL)-8 levels and
cellular composition of the vitreous humor in proliferative
diabetic retinopathy, proliferative vitreoretinopathy, and
traumatic proliferative vitreoretinopathy. Ocul Immunol
Inﬂamm 2005; 13: 375–381.
16 Grisanti S, Heimann K, Wiedemann P. Immune response to
speciﬁc molecules of the retina in proliferative vitreoretinal
disorders. Graefes Arch Clin Exp Ophthalmol 1994; 232:
302–307.
17 Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal
ﬁbrosis–a controlled clinical study of systemic steroid
therapy. Graefes Arch Clin Exp Ophthalmol 1982; 219: 268–271.
18 Beissert S, Schwarz A, Schwarz T. Regulatory T cells.
Invest Dermatol 2006; 126: 15–24.
19 Mombarets P, Lacomini J, Johnson RS, Herrup K,
Tonegawa S, Papaioannou VE. RAG-1-deﬁcient mice have
no mature B and T lymphocytes. Cell 1992; 68: 869–877.
20 Barnden MJ, Allison J, Heath WR, Carbone FR. Defective
TCR expression in transgenic mice constructed using
cDNA-based alpha- and beta-chain genes under the control
of heterologous regulatory elements. Immunol Cell Biol 1998;
76: 34–40.
21 Canto ´ Soler MV, Gallo JE, Dodds RA, Suburo AM.
A mouse model of proliferative vitreoretinopathy
induced by dispase. Exp Eye Res 2002; 75: 491–504.
22 Kralinger MT, Kieselbach GF, Voigt M, Hayden B,
Hernandez E, Fernandez V et al. Experimental model for
proliferative vitreoretinopathy by intravitreal dispase: limited
by zonulolysis and cataract. Ophthalmologica 2006; 220: 211–216.
23 Marmor MF, Holder GE, Seeliger MW, Yamamoto S.
International Society for Clinical Electrophysiology of
Vision. Standard for clinical electroretinography
(2004 update). Doc Ophthalmol 2004; 108: 107–114.
24 Bali E, Willermain F, Caspers-Velu L, Dubois C, Dehou MF,
Velu T et al. IL-10 in vivo gene expression in a cell-induced
animal model of proliferative vitreoretinopathy. Int J Mol
Med 2003; 12: 305–310.
25 Qian S, Li W, Li Y, Fu F, Lu L, Fung JJ et al. Systemic
administration of cellular interleukin-10 can exacerbate
cardiac allograft rejection in mice. Transplantation 1996;
62: 1709–1714.
26 Sontheimer RD. Subacute cutaneous lupus erythematosus:
25-year evolution of a prototypic subset (subphenotype) of
lupus erythematosus deﬁned by characteristic cutaneous,
pathological, immunological, and genetic ﬁndings.
Autoimmun Rev 2005; 4: 253–263.
27 Uchio E, Kijima M, Ishioka M, Tanaka S, Ohno S.
Suppression of actively induced experimental autoimmune
uveoretinitis by CD4þ T cells. Graefes Arch Clin Exp
Ophthalmol 1997; 235: 97–102.
28 Hofstetter HH, Kovalovsky A, Shive CL, Lehmann PV,
Forsthuber TG. Neonatal induction of myelin-speciﬁc
Th1/Th17 immunity does not result in experimental
autoimmune encephalomyelitis and can protect against
the disease in adulthood. J Neuroimmunol 2007; 187: 20–30.
29 Sorokin L. The impact of the extra cellar matrix on
inﬂammation. Nat Rev Immunol 2010; 10: 712–723.
Assessment of the innate and adaptive immune system in PVR
W Zhang et al
880
Eye30 Machemer R, Norton EW. Experimental retinal detachment
in the owl monkey: methods of production and clinical
picture. Am J Ophthalmol 1968; 66: 388–395.
31 Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson
DS. A new model of proliferative vitreoretinopathy. Invest
Ophthalmol Vis Sci 1998; 39: 2157–2164.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
Derivative Works 3.0 Unported License. To view a copy
of this license, visit http://creativecommons.org/licenses/
by-nc-nd/3.0/
Assessment of the innate and adaptive immune system in PVR
W Zhang et al
881
Eye